Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Dermatofibrosarcoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Doxorubicin 9Imatinib Mesylate 6pazopanib 4Ifosfamide 4Radiotherapy 3Gemcitabine 3Docetaxel 3pembrolizumab 2Radiation 2Neoadjuvant Therapy 2Mohs Surgery 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2selinexor 1saracatinib 1sapanisertib 1ribociclib 1peposertib 1liposomal doxorubicin 1indolepropanol phosphate 1envafolimab 1cixutumumab 1brigimadlin 1avelumab 1X-Rays 1Watchful Waiting 1TTI-621 1Sunitinib 1Specimen Handling 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dermatofibrosarcoma × MLN 8237 × Sarcoma × Clear all
NCT01653028 2017-11-30

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡